A carregar...
Ruxolitinib for the management of myelofibrosis: Results of an international physician survey
BACKGROUND: Ruxolitinib is established as treatment for symptomatic myeloproliferative neoplasm (MPN)-associated myelofibrosis. The strict inclusion and exclusion criteria and dose modification rules that applied to the COMFORTI and II studies that led to the licensing of ruxolitinib are not always...
Na minha lista:
| Publicado no: | Leuk Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8190959/ https://ncbi.nlm.nih.gov/pubmed/28843161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2017.08.002 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|